Clopidogrel

Clopidogrel (CAS No.: 113665-84-2) is a small-molecule P2Y12 receptor antagonist classified as a platelet aggregation inhibitor, widely utilized in biomedical research to investigate purinergic signaling and platelet activation pathways. By selectively targeting the ADP-responsive P2Y12 receptor on platelets, clopidogrel interferes with downstream signaling events that regulate platelet activation, aggregation, and thrombus formation, making it a valuable tool for studying hemostasis and thrombosis-related mechanisms in vitro and in vivo. Its activity is typically characterized within the nanomolar to micromolar concentration range depending on experimental conditions, and it is frequently employed in cell-based assays and animal models to examine platelet function, receptor pharmacology, and the molecular basis of vascular occlusive processes. In drug discovery settings, clopidogrel serves as a reference compound for evaluating P2Y12-targeted modulators and for dissecting signaling cascades associated with ADP-mediated platelet responses, with experimental dosing and exposure parameters varying according to specific assay systems and research objectives.